ClinicalTrials.gg
CompletedNCT03926195MANTA-RAyUpdated Apr 30, 2024Results posted

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

A Phase 2 interventional study of Filgotinib and Placebo in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis, sponsored by Galapagos NV. Completed at 71 sites in 8 countries. Open to male participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
10th of 17
109 · median 287
Started
2019
the only one that year
Phase 2
6 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
6 of 17
Galapagos NV

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 10th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 2, and was the 11th registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 21 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.

Results of this study may be pooled with the results of a separate study being conducted in participants with inflammatory bowel disease (Protocol GS-US-418-4279; NCT03201445) with the same objective.

03

Conditions studied

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Non-Radiographical Axial Spondyloarthritis
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or, non-radiographic axial spondyloarthritis for at least 12 weeks prior to screening, meeting the corresponding specific disease classification criteria as specified in the protocol

Key Exclusion Criteria:

  • Previously documented problems with male reproductive health
  • Prior diagnosis of male infertility
  • Use of any prohibited concomitant medication as outlined by protocol

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Filgotinib

    Participants received filgotinib 200 milligrams (mg) tablet, orally, once daily up to Week 13 in the double-blind (DB) phase. At Week 13, participants who were arthritis responders, were unblinded and received open-label (OL) treatment filgotinib 200 mg, tablet, orally, once daily up to approximately 143 weeks (until Week 156) in the extension (EXT) phase and participants who were arthritis nonresponders discontinued blinded study drug and started standard of care (SOC) treatment in the EXT phase. Participants on DB treatment or OL filgotinib who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) discontinued the study drug and started SOC for up to 52 weeks.

    Drug: Filgotinib · Drug: Standard of Care

  • Placebo comparator
    Placebo

    Participants received placebo (matched to filgotinib) tablet, orally, once daily up to Week 13 in the DB phase. At Week 13, participants were unblinded and started SOC treatment in the EXT phase for up to approximately 143 weeks (until Week 156). Participants who entered the monitoring phase (if their sperm parameters met ≥50% decrease threshold in pre-specified semen parameters) continued on SOC treatment.

    Drug: Placebo · Drug: Standard of Care

Interventions

  • 200-mg tablet administered orally once daily

    Also known as: GS-6034, Jyseleca®

  • DrugPlacebo

    Placebo to match filgotinib tablet administered orally once daily

  • DrugStandard of Care

    Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13

    Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.

    Time frame: Baseline to Week 13

Secondary outcomes

  1. Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26

    Arthritis responder: For rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nrAxSpA), a participant with an improvement in the Physician's Global Assessment of Disease Activity (PhGADA) of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a visual analogue scale (VAS) ranged from 0 (no disease)-100 (worst disease) millimeters (mm). Baseline value for sperm/semen parameters was the mean of 2 evaluable semen collections at the screening visit. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 26 - baseline\] / baseline) × 100; value at Week 26 was the mean of 2 evaluable samples collected at Week 26.

    Time frame: Baseline to Week 26

  2. Change From Baseline in Sperm Total Motility at Week 13

    The normal range for sperm total motility is ≥40%.

    Time frame: Baseline, Week 13

  3. Change From Baseline in Sperm Total Motility at Week 26

    Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm total motility is ≥40%.

    Time frame: Baseline, Week 26

  4. Change From Baseline in Total Sperm Count at Week 13

    The normal range for total sperm count is ≥ 39 million sperms/ejaculate.

    Time frame: Baseline, Week 13

  5. Change From Baseline in Total Sperm Count at Week 26

    Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for total sperm count is ≥ 39 million sperms/ejaculate.

    Time frame: Baseline, Week 26

  6. Change From Baseline in Sperm Concentration at Week 13

    The normal range for sperm concentration is ≥15 million sperms/mL.

    Time frame: Baseline, Week 13

  7. Change From Baseline in Sperm Concentration at Week 26

    Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm concentration is ≥15 million sperms/mL.

    Time frame: Baseline, Week 26

  8. Change From Baseline in Ejaculate Volume at Week 13

    The normal range for ejaculate volume is ≥1.5 mL.

    Time frame: Baseline, Week 13

  9. Change From Baseline in Ejaculate Volume at Week 26

    Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for ejaculate volume is ≥1.5 mL.

    Time frame: Baseline, Week 26

  10. Change From Baseline in Percent Normal Sperm Morphology at Week 13

    The normal range for percent normal sperm morphology is ≥30% normal sperms.

    Time frame: Baseline, Week 13

  11. Change From Baseline in Percent Normal Sperm Morphology at Week 26

    Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for percent normal sperm morphology is ≥30% normal sperms.

    Time frame: Baseline, Week 26

07

Results

Posted Aug 1, 2023

Participant flow

Participants were enrolled at study sites in Bulgaria, Czech Republic, Estonia, Georgia, Latvia, Poland, Spain, and Ukraine. The first participant was screened on 28 May 2019. A total of 308 participants were screened of which 109 participants were randomized into the study.

DB Treatment Phase (Through Week 13)
Participant flow — DB Treatment Phase (Through Week 13)
MilestoneFilgonitibPlacebo
Started5455
Completed5453
Not completed02
Withdrew: Withdrawal by subject02
EXT Phase (Through Week 156)
Participant flow — EXT Phase (Through Week 156)
MilestoneFilgonitibPlacebo
Started4649
Completed2426
Not completed2223
Withdrew: Adverse event51
Withdrew: Pre-specified decrease in sperm parameters1617
Withdrew: Withdrawal by subject13
Withdrew: Physician decision02
Monitoring Phase (52 Weeks)
Participant flow — Monitoring Phase (52 Weeks)
MilestoneFilgonitibPlacebo
Started2721
Completed2720
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13

Baseline for sperm/semen parameters was the mean of 2 evaluable semen samples at screening. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 13 - baseline\] / baseline) × 100; value at Week 13 was the mean of 2 evaluable samples collected at Week 13.

Time frame:
Baseline to Week 13
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 13
percentage of participantsFilgonitibPlacebo
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 1313.07.5
Statistical analysis
  • Filgonitib vs Placebo · Difference in percentage: 5.8 · 95% CI -7.5 to 19.2Difference in percentage and 95% confidence interval (CI) was based on a stratified Mantel-Haenszel test.
SecondaryPercentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26

Arthritis responder: For rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nrAxSpA), a participant with an improvement in the Physician's Global Assessment of Disease Activity (PhGADA) of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a visual analogue scale (VAS) ranged from 0 (no disease)-100 (worst disease) millimeters (mm). Baseline value for sperm/semen parameters was the mean of 2 evaluable semen collections at the screening visit. The normal range for sperm concentration is ≥15 million sperms/mL. Percentage change = (\[mean at Week 26 - baseline\] / baseline) × 100; value at Week 26 was the mean of 2 evaluable samples collected at Week 26.

Time frame:
Baseline to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 26
percentage of participantsFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Percentage of Participants With a ≥ 50% Decrease From Baseline in Sperm Concentration at Week 2610.38.014.30
SecondaryChange From Baseline in Sperm Total Motility at Week 13

The normal range for sperm total motility is ≥40%.

Time frame:
Baseline, Week 13
Reported as:
Median · percentage of motile sperms
Change From Baseline in Sperm Total Motility at Week 13
percentage of motile spermsFilgonitibPlacebo
Change From Baseline in Sperm Total Motility at Week 13-2.3 (-8.1 to 1.4)-1.7 (-5.8 to 0.7)
Statistical analysis
  • Filgonitib vs Placebo · Median difference (final values): -1.5 · 95% CI -6.4 to 3.5Difference in Medians and 95% CI for change from baseline at Week 13 was based on quantile regression.
SecondaryChange From Baseline in Sperm Total Motility at Week 26

Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm total motility is ≥40%.

Time frame:
Baseline, Week 26
Reported as:
Median · percentage of motile sperms
Change From Baseline in Sperm Total Motility at Week 26
percentage of motile spermsFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Change From Baseline in Sperm Total Motility at Week 26-2.4 (-9.3 to 1.0)0.9 (-5.2 to 6.3)-1.4 (-13.3 to 13.0)-2.8 (-8.5 to 2.9)
SecondaryChange From Baseline in Total Sperm Count at Week 13

The normal range for total sperm count is ≥ 39 million sperms/ejaculate.

Time frame:
Baseline, Week 13
Reported as:
Median · million sperms/ejaculate
Change From Baseline in Total Sperm Count at Week 13
million sperms/ejaculateFilgonitibPlacebo
Change From Baseline in Total Sperm Count at Week 13-2.1 (-41.7 to 31.0)-9.6 (-36.2 to 18.0)
Statistical analysis
  • Filgonitib vs Placebo · Median difference (final values): -0.2 · 95% CI -37.1 to 36.8Difference in medians and 95% CI for change from baseline at Week 13 was based on quantile regression.
SecondaryChange From Baseline in Total Sperm Count at Week 26

Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for total sperm count is ≥ 39 million sperms/ejaculate.

Time frame:
Baseline, Week 26
Reported as:
Median · million sperms/ejaculate
Change From Baseline in Total Sperm Count at Week 26
million sperms/ejaculateFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Change From Baseline in Total Sperm Count at Week 26-0.2 (-39.5 to 44.5)16.8 (-49.3 to 60.6)32.2 (-60.8 to 121.3)-29.9 (-79.8 to 36.6)
SecondaryChange From Baseline in Sperm Concentration at Week 13

The normal range for sperm concentration is ≥15 million sperms/mL.

Time frame:
Baseline, Week 13
Reported as:
Median · million sperms/mL
Change From Baseline in Sperm Concentration at Week 13
million sperms/mLFilgonitibPlacebo
Change From Baseline in Sperm Concentration at Week 133.7 (-7.2 to 13.1)-0.4 (-6.1 to 7.8)
Statistical analysis
  • Filgonitib vs Placebo · Median difference (final values): 7.4 · 95% CI -6.0 to 20.8Difference in Medians and 95% CI for change from baseline at Week 13 was based on quantile regression.
SecondaryChange From Baseline in Sperm Concentration at Week 26

Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for sperm concentration is ≥15 million sperms/mL.

Time frame:
Baseline, Week 26
Reported as:
Median · million sperms/mL
Change From Baseline in Sperm Concentration at Week 26
million sperms/mLFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Change From Baseline in Sperm Concentration at Week 261.7 (-8.9 to 21.2)9.6 (-3.7 to 29.0)10.3 (-43.5 to 36.3)-5.8 (-12.9 to 4.6)
SecondaryChange From Baseline in Ejaculate Volume at Week 13

The normal range for ejaculate volume is ≥1.5 mL.

Time frame:
Baseline, Week 13
Reported as:
Median · mL
Change From Baseline in Ejaculate Volume at Week 13
mLFilgonitibPlacebo
Change From Baseline in Ejaculate Volume at Week 13-0.3 (-0.6 to 0.1)-0.2 (-0.4 to 0.1)
Statistical analysis
  • Filgonitib vs Placebo · Median difference (final values): -0.3 · 95% CI -0.6 to 0.1Difference in Medians and 95% CI for change from baseline at Week 13 was based on quantile regression.
SecondaryChange From Baseline in Ejaculate Volume at Week 26

Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for ejaculate volume is ≥1.5 mL.

Time frame:
Baseline, Week 26
Reported as:
Median · mL
Change From Baseline in Ejaculate Volume at Week 26
mLFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Change From Baseline in Ejaculate Volume at Week 26-0.2 (-0.7 to 0.4)-0.6 (-0.7 to -0.2)0.2 (-1.0 to 1.1)-0.3 (-0.6 to 0.2)
SecondaryChange From Baseline in Percent Normal Sperm Morphology at Week 13

The normal range for percent normal sperm morphology is ≥30% normal sperms.

Time frame:
Baseline, Week 13
Reported as:
Median · percentage of normal sperms
Change From Baseline in Percent Normal Sperm Morphology at Week 13
percentage of normal spermsFilgonitibPlacebo
Change From Baseline in Percent Normal Sperm Morphology at Week 131 (-1 to 2)1 (-1 to 3)
Statistical analysis
  • Filgonitib vs Placebo · Median difference (final values): -1 · 95% CI -3 to 1Difference in Medians and 95% CI for change from baseline at Week 13 was based on quantile regression.
SecondaryChange From Baseline in Percent Normal Sperm Morphology at Week 26

Arthritis responder: For RA, PsA, AS, and nrAxSpA, a participant with an improvement in the PhGADA of at least 20% compared with baseline (Day 1) at the specified assessment time. Arthritis nonresponder: For RA, PsA, AS, or nrAxSpA, a participant who did not fulfill the definition of arthritis responder at the specified assessment timepoint. PhGADA: Physician measured the participant's disease severity on a VAS ranged from 0 (no disease)-100 (worst disease) mm. The normal range for percent normal sperm morphology is ≥30% normal sperms.

Time frame:
Baseline, Week 26
Reported as:
Median · percentage of normal sperms
Change From Baseline in Percent Normal Sperm Morphology at Week 26
percentage of normal spermsFilgotinib/OL Filgotinib (Responder)Placebo/SOC (Responder)Filgotinib/SOC (Nonresponder)Placebo/SOC (Nonresponder)
Change From Baseline in Percent Normal Sperm Morphology at Week 261 (-2 to 5)3 (-2 to 8)3 (-15 to 6)4 (1 to 8)

Adverse events

Collected over From first dose up to Week 156. TEAEs were considered as AEs with onset on or after the first dose of study drug to the last dose + 30 days. AEs leading to premature discontinuation study drug was also a TEAE.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Phase: Filgotinib 200 mg0/54 (0%)2/54 (3.7%)12/54 (22.2%)
Double-Blind Phase: Placebo0/55 (0%)1/55 (1.8%)10/55 (18.2%)
Extension Phase: Placebo - SOC0/49 (0%)2/49 (4.1%)23/49 (46.9%)
Extension Phase: Filgotinib 200 mg - SOC0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Extension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg0/39 (0%)5/39 (12.8%)20/39 (51.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventDouble-Blind Phase: Filgotinib 200 mgDouble-Blind Phase: PlaceboExtension Phase: Placebo - SOCExtension Phase: Filgotinib 200 mg - SOCExtension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg
AppendicitisInfections and infestations0/540/550/491/70/39
Meniscus injuryInjury, poisoning and procedural complications0/540/552/490/70/39
Lower limb fractureInjury, poisoning and procedural complications0/540/550/490/71/39
RadiculopathyNervous system disorders0/540/550/490/71/39
UveitisEye disorders0/540/550/490/71/39
NephrolithiasisRenal and urinary disorders0/540/550/490/71/39
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/540/550/490/71/39
COVID-19 pneumoniaInfections and infestations0/540/550/490/71/39
Ligament ruptureInjury, poisoning and procedural complications0/540/551/490/70/39
EpistaxisRespiratory, thoracic and mediastinal disorders1/540/550/490/70/39
Most frequent other events
Showing 10 of 30
Most frequent other events
EventDouble-Blind Phase: Filgotinib 200 mgDouble-Blind Phase: PlaceboExtension Phase: Placebo - SOCExtension Phase: Filgotinib 200 mg - SOCExtension Phase: Filgotinib 200 mg - OL Filgotinib 200 mg
NasopharyngitisInfections and infestations4/544/553/494/72/39
COVID-19Infections and infestations0/540/5510/493/76/39
Drug hypersensitivityImmune system disorders0/540/550/491/70/39
Seasonal allergyImmune system disorders0/540/550/491/71/39
Rhinitis allergicRespiratory, thoracic and mediastinal disorders0/540/550/491/70/39
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/540/550/491/70/39
Alanine aminotransferase increasedInvestigations0/540/552/491/71/39
HeadacheNervous system disorders2/541/552/491/72/39
SciaticaNervous system disorders0/540/551/491/70/39
External ear painEar and labyrinth disorders0/540/550/491/70/39

Baseline characteristics

The Safety Analysis Set included all randomized participants who took ≥ 1 dose of double-blind study drug.

Age, Continuous
Age, Continuous(years)FilgonitibPlaceboTotal
Mean40 ± 8.539 ± 7.840 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)FilgonitibPlaceboTotal
Female000
Male5455109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FilgonitibPlaceboTotal
Hispanic or Latino101
Not Hispanic or Latino5355108
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FilgonitibPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5455109
More than one race000
Unknown or Not Reported000
Sperm Concentration
Sperm Concentration(million sperms/milliliter (mL))FilgonitibPlaceboTotal
Mean71.2 ± 41.0066.9 ± 38.7269.0 ± 39.74
Total Sperm Count
Total Sperm Count(million sperms/ejaculate)FilgonitibPlaceboTotal
Mean208.4 ± 136.94225.2 ± 137.39216.9 ± 136.79
Sperm Total Motility
Sperm Total Motility(percentage of motile sperm)FilgonitibPlaceboTotal
Mean55.9 ± 8.9958.2 ± 8.4857.1 ± 8.77
Ejaculate Volume
Ejaculate Volume(mL)FilgonitibPlaceboTotal
Mean3.1 ± 1.263.5 ± 1.293.3 ± 1.29

1 further baseline measures are reported on the registry.

08

Study locations

71 sites
  • Medical center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • UMHAT Pulmed OOD
    Plovdiv, 4000, Bulgaria
  • UMHAT Sv. Georgi, EAD
    Plovdiv, 4000, Bulgaria
  • MHAT "Eurohospital" - Plovdiv, OOD
    Plovdiv, 4002, Bulgaria
  • Medical Center Teodora, EOOD
    Ruse, 7000, Bulgaria
  • Medizinski Zentar-1-Sevlievo EOOD
    Sevlievo, 5400, Bulgaria
  • Medical Center Excelsior, OOD
    Sofia, 1407, Bulgaria
  • DCC Alexandrovska, EOOD
    Sofia, 1431, Bulgaria
  • UMHAT Sv. Ivan Rilski, EAD
    Sofia, 1431, Bulgaria
  • DCC 17 - Sofia EOOD
    Sofia, 1504, Bulgaria
  • Meditsinski Centar - Izgrev EOOD
    Sofia, 1606, Bulgaria
  • MC Synexus - Sofia, EOOD
    Sofia, 1784, Bulgaria
  • CCR Brno S.r.o.
    Brno, 60200, Czechia
  • CCBR Ostrava s.r.o
    Ostrava, 702 00, Czechia
  • Vesalion s.r.o.
    Ostrava, 702 00, Czechia
  • MUDr. Rosypalova s.r.o.
    Ostrava, 708 00, Czechia
  • Bioclinica Pardubice
    Pardubice, 530 02, Czechia
  • CLINTRIAL s.r.o.
    Praha, 10000, Czechia
  • Revmatologicky Ustav
    Praha, 128 52, Czechia
  • Thomayerova nemocnice
    Praha, 140 59, Czechia
  • MUDr Zuzana Stejfova Revmatologicka ambulance
    Praha, 14000, Czechia
  • Affidea Praha s.r.o.
    Praha, 14800, Czechia
  • MEDICAL PLUS s.r.o.
    Uherské Hradiště, 68601, Czechia
  • OÜ Innomedica
    Tallinn, 10117, Estonia
  • Center for Clinical and Basic Research
    Tallinn, 10128, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Clinical Research Centre
    Tartu, 50106, Estonia
  • Meditrials OU
    Tartu, 50406, Estonia
  • Chapidze Emergency Cardiology Center
    Tbilisi, 0159, Georgia
  • Institute of Clinical Cardiology Ltd
    Tbilisi, 0159, Georgia
  • National Institute of Endocrinology
    Tbilisi, 0159, Georgia
  • Tbilisi Heart and Vascular Clinic Ltd
    Tbilisi, 0159, Georgia
  • Aversi ClinicLtd.
    Tbilisi, 0160, Georgia
  • Clinic on Mtskheta Street
    Tbilisi, 0179, Georgia
  • Consilium Medulla-multiprofile clinic Ltd
    Tbilisi, 0186, Georgia
  • Medicore Ltd.
    Tbilisi, 0186, Georgia
  • M&M center
    Ādaži, LV2164, Latvia
  • Nasz Lekarz Osrodek Badan Klinicznych
    Bydgoszcz, 85-065, Poland
  • Szpital Uniwersytecki nr 2 im. dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Silmedic sp. z o.o
    Katowice, 40-282, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Maciej Zymla
    Knurów, 44-190, Poland
  • Zespol Poradni Specjalistycznych REUMED
    Lublin, 20-607, Poland
  • SOLUMED Centrum Medyczne
    Poznań, 60-529, Poland
  • Centrum Badan Klinicznych S.C.
    Poznań, 60-773, Poland
  • Ai Centrum Medyczne Sp. Z O.O. Sp.K.
    Poznań, 61-113, Poland
  • RCMed
    Sochaczew, 96-500, Poland
  • Medycyna Kliniczna
    Warsaw, 00-874, Poland
  • Centrum Medyczne AMED
    Warszawa, 03-291, Poland
  • Centrum Medyczne AMED
    Łódź, 91-363, Poland
  • Clinica GAIAS
    Santiago, 15702, Spain
  • CI Dnipropetrovsk CMCH #4 RC
    Dnipro, 49102, Ukraine
  • Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU
    Ivano-Frankivs'k, 76008, Ukraine
  • GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
    Kharkiv, 61039, Ukraine
  • CHI Kharkiv City Clinical Hospital #13
    Kharkiv, 61124, Ukraine
  • CI A.and O. Tropiny City Clinical Hospital
    Kherson, 73000, Ukraine
  • Medical Center of Limited Liability Company Medical Clinic Blagomed
    Kyiv, 01023, Ukraine
  • Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC
    Kyiv, 02091, Ukraine
  • SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU
    Kyiv, 03680, Ukraine
  • Limited Liability Company Medical Center Concilium Medical
    Kyiv, 04050, Ukraine
  • LLC Treatment-Diagnostic Center ADONIS plus
    Kyiv, 04050, Ukraine
  • Volyn Regional Clinical Hospital
    Luts'k, 43005, Ukraine
  • Lviv Regional Clinical Hospital Dept of Rheumatology NMU
    Lviv, 79000, Ukraine
  • Mil&Med Cl C of Lviv of the St Border Service of Ukraine
    Lviv, 79049, Ukraine
  • Center of Reconstructive & Restorative Medicine of Odessa National Medical University
    Odesa, 65000, Ukraine
  • M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA
    Poltava, 36011, Ukraine
  • Ternopil University Hospital, Dept. of Rheumatology, SHEI I.Ya.Horbachevskyi Ternopil SMU
    Ternopil, 46002, Ukraine
  • Private Small Enterprise Medical Center Pulse
    Vinnytsia, 21001, Ukraine
  • Vinnytsia M.I.Pyrogov RCH Dept of cardiology NMU
    Vinnytsia, 21018, Ukraine
  • MCIC Health Clinic BO LTD TDC Slaomed
    Vinnytsia, 21029, Ukraine
  • CI CCH #6 Dept of Therapy ZSMU
    Zaporizhzhya, 69035, Ukraine
  • CI Zaporizhzhia Regional Clinical Hospital of ZRC
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Publications

  • Hellstrom WJG, Dolhain RJEM, Ritter TE, Watkins TR, Arterburn SJ, Dekkers G, Gillen A, Tonussi C, Gilles L, Oortwijn A, Van Beneden K, de Vries DE, Sikka SC, Vanderschueren D, Reinisch W. MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Adv Ther. 2022 Jul;39(7):3403-3422. doi: 10.1007/s12325-022-02168-4. Epub 2022 May 25. PubMed 35614292 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Aug 2020, 14 months.

Results were first posted in Aug 2023, 2 years 11 months after primary completion. A results delay was requested in Jul 2021.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 14 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2019
First posted
Apr 24, 2019
StartActual
May 28, 2019
Primary completionActual
Aug 14, 2020
CompletionActual
May 10, 2023
Results delay requested
Jul 27, 2021
Results first posted
Aug 1, 2023
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03926195
Lead sponsor
Galapagos NV
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
May 28, 2019
Primary completion
Aug 14, 2020
Completion
May 10, 2023
Results posted
Aug 1, 2023
Last update
Apr 30, 2024

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion